Dr. Simon on the Importance of Next-Generation Sequencing in NSCLC

Partner | Cancer Centers | <b>Moffitt</b>

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

George Simon, MD, FACP, FCCP, executive director, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, discusses the importance of next-generation sequencing (NGS) in patients with non–small cell lung cancer (NSCLC).

NGS should be performed for all patients with this disease, especially those with nonsquamous disease, and those who are never-smokers, according to Simon. However, a significant number of patients still do not receive this testing, Simon adds. NGS could provide an opportunity to identify those who would benefit from targeted treatment approaches, Simon concludes.